Literature DB >> 24194648

Abnormal uterine bleeding as a presenting symptom is related to multiple uterine leiomyoma: an ultrasound-based study.

José Alberto Fonseca-Moutinho1, Lígia Silva Barbosa, Daniel Gonçalves Torres, Sara Morgado Nunes.   

Abstract

PURPOSE: To determine the prevalence of uterine leiomyomas, diagnosed by ultrasound, in a private health care setting located in the central eastern region of Portugal, and to explore the demographic and clinical factors related to diagnosis and symptomatology. PATIENTS AND METHODS: The files of 624 patients attending a private clinic in Covilhã, Portugal, from January 2 to December 31, 2010 were retrieved for evaluation. Pelvic ultrasound record, age, weight, height, age at menarche, number of pregnancies and deliveries, marital status, menstrual cycles characteristic, and contraceptive method at consultation were included in the analysis.
RESULTS: Uterine leiomyoma (UL) was diagnosed by ultrasonography in 161 (25.8%) patients. A single UL was diagnosed in 80 (49.7%) patients. In 79 (49.1%) patients, the largest leiomyoma had a dimension <20 mm. Prevalence of UL was age dependent: at 11.0% for women 20-39 years old; 45.4% for those aged 40-59 years; and 19.5% for women 60 years or older. Metrorrhagia was the most distressing presenting symptom. When menorrhagia was the presenting symptom, the probability of having an ultrasound diagnosis of UL was 73.3%. Metrorrhagia or menorrhagia, as presenting symptom, was significantly related to the ultrasound diagnosis of multiple ULs.
CONCLUSION: UL was especially prevalent in women aged between 40 and 59 years. Patients with multiple ULs had significantly more abnormal uterine bleeding. In patients with menorrhagia or metrorrhagia, special attention should be taken in searching for the presence of multiple ULs during ultrasound.

Entities:  

Keywords:  fibroid; leiomyoma; menorrhagia; metrorrhagia; prevalence; ultrasound

Year:  2013        PMID: 24194648      PMCID: PMC3814927          DOI: 10.2147/IJWH.S50786

Source DB:  PubMed          Journal:  Int J Womens Health        ISSN: 1179-1411


Introduction

Leiomyomas, also known as fibroids, are the most frequent benign uterine tumors to develop during a woman’s reproductive years; occurrence tends to regress after menopause.1 Malign transformation of uterine leiomyoma (UL) seems to be a very rare event,2 but they are symptomatic in 20%–30% of cases and are the main reason for approximately one-third of all hysterectomies in developed countries.3,4 Symptoms related to UL are menstrual disorders, mainly menorrhagia, pelvic pain, and infertility, which can adversely affect pregnancy outcomes.5,6 UL disproportionately affects Black women.4,7,8 The etiology of UL is unknown, but it can be influenced by genetic liability,9 hormonal environment,10,11 and local tissue mediators.10,12 Definitive prevalence of UL in the general female population is also unknown, but differs by ethnicity, age, and method used for diagnosis.13 In clinical practice, transvaginal ultrasonography (TVS) is the most widespread method for evaluating UL, with an estimated accuracy of 87%–92%.14–16 The objective of this study was to determine the prevalence of UL, diagnosed by TVS, at a private health care setting located in the central eastern part of Portugal, and to explore the demographic and clinical factors related to diagnosis and symptomatology.

Materials and methods

The study retrospectively analyzed the medical files of all female patients who consecutively attended a gynecological consultation at a private health care setting located in Covilhã, Portugal, from December 2–31, 2010. Excluded from the study were virgins, patients who had previously undergone a hysterectomy, or those pregnant at the time of the consultation. All included patients were Caucasian, except three, who were African. The same gynecologist (JAF), who has more than 20 years of gynecological experience and competence in the practice of gynecologic ultrasound, attended all patients. Policies of the private clinic include recording of demographic and clinical data from every patient in a standard digital database. In all cases, an office TVS was offered to the patient. The sonographic equipment used was a Nemio 17 (SSA-550A) with a PVM-651VT 6 MHz endovaginal probe (Toshiba Corporation, Tokyo, Japan). For the anonymous use of data from patient files, written consent was obtained from the clinical director of the private health care clinic. LSB and DGT analyzed the files of 624 patients who met the inclusion criteria, and from each file they retrieved age, weight, height, age at menarche, number of pregnancies and deliveries, marital status, menstrual cycles characteristics, and contraceptive method at time of consultation. The presence, number, and largest dimension of the ULs were retrieved from TVS records. For analysis, the data recorded at the first consultation in 2010 were considered. Ultrasound records were analyzed for the presence or absence of UL, their number, location and largest dimension. The data were organized and analyzed in Statistical Package for the Social Sciences® software ([SPSS] v 20.0 for Windows; IBM Corporation, Armonk, NY, USA), by SMN. Univariate analysis and multivariate logistic regression analysis were performed. In all cases, P < 0.05 was considered significant.

Results

Using TVS, UL was diagnosed in 161 (25.8%) of those 624 cases included in the study. From those 161 patients with an ultrasound-based diagnosis of UL, 99 (61.5%) had previous knowledge of the disease. In three patients, resectoscopic myomectomy was proposed for treating symptomatic sub-mucous leiomyoma. The demographic characteristics of the studied population are shown in Table 1. The mean age was 39.6 years; 66.2% of the women were married; 68.2% reported having had at least one pregnancy and 64.2% at least one delivery; 31.6% were asymptomatic. UL was diagnosed by ultrasound in 11.0% of all women aged 20 to 39 years old, in 45.4% of all women aged 40 to 59 years, and in 19.5% of all women aged 60 years or more. Metrorrhagia and menorrhagia were the most usual presenting symptoms, and were recorded in 11.3% of all cases and in 22.3% of all women with an ultrasound diagnosis of UL.
Table 1

Demographic characteristics (624 cases)

Demographic dataTotal (624 cases)
Leiomyoma (161 cases)
n%n%
Age (years)
 Range15–7721–71
 Median39.6246.65
 19 or less121.900
 20–3930949.53421.1
 40–5926242.011973.9
 60 or more416.685.0
Education
 High school or less39463.110867.1
 College or more23036.95332.9
Marital status
 Married41366.212778.9
 Single15524.8138.0
 Divorced335.3127.5
 Widowed233.795.6
Body mass index
 18.4 or less203.231.9
 18.5–24.937159.57647.2
 25–29.916927.15634.8
 30 or more6410.32616.1
Age at menarch (years)
 12 or less31250.08150.0
 13 or more31250.08050.0
Number of pregnancies
 019831.72113.0
 115625.05433.5
 216326.15031.1
 3 or more10717.13622.4
Number of deliveries
 022335.72817.4
 116326.16037.3
 2 or more23838.17345.3
Miscarriage
 Total426140
 No33478.410575.0
 Yes9221.63525.0
Cesarean section
 Total401133
 No one32180.010981.9
 One or more8020.02418.1
Contraception
 Combined pill20733.22918.0
 Progestin pill or hormonal IUD548.7169.9
 Other36358.111672.1
Presenting symptom
 Screening (asymptomatic)19731.64729.2
 Metrorrhagia6710.72515.5
 Menorrhagia152.4116.8
 Pelvic pain619.82012.4
 Vulvar symptoms669.6138.1
 Breast symptoms477.5127.5
 Leukorrhea365.863.7
 Contraception counseling315.053.1
 Infertility counseling213.400
 Other899.32213.7

Abbreviation: IUD, intrauterine device.

The uterus was explored with clinical bimanual palpation and TVS. Results of clinical and ultrasound exploration of the uterus are shown in Table 2. The overall prevalence of UL was 17.0% by bimanual palpation and 25.8% by TVS. ULs larger than 3.0 cm were identified through ultrasound imaging in 24.2% of the cases.
Table 2

Clinical and ultrasound uterus exploration data (624 cases)

Clinical and ultrasound dataN%
Uterine size at gynecological examination
 Normal size51883.0
 Uterine enlargement10617.0
Uterine leiomyoma at ultrasound
 Yes16125.8
 No46374.2
Number of leiomyomas at ultrasound (161 women)
 Single8049.7
 Multiple8150.3
Dimension of largest leiomyoma at ultrasound (161 women)
 <20 mm7949.1
 20–29 mm4326.7
 30–39 mm1811.2
 40–49 mm116.8
 >50 mm106.2
Previous patient knowledge about leiomyoma (161 women)
 Yes9961.5
 No6238.5
In order to uncover significant demographic and clinical differences between women with and without ultrasound diagnosis of UL, a univariate analysis was performed (Table 3). Significant factors associated with an ultrasound-based diagnosis of UL were the following: 40 to 59 years of age; married; excessive body weight (obese); prior pregnancy or delivery; non-use of the combined pill for contraception; and symptoms of menorrhagia. However, after adjustment by multivariate logistic regression analysis, age 40 to 59 years remained the single demographic and clinical factor found to be statistically associated with ultrasonographic diagnosis of UL.
Table 3

Univariate analysis of demographic and clinical characteristics between patients with and without sonographic diagnosis of uterine leiomyoma

Demographic and clinical dataUterine leiomyoma at ultrasound
P-value
NoYes
Age (years)
 19 or less100.0%0.0%0.0001
 20–3989.0%11.0%
 40–5954.6%45.4%
 60 or more80.5%19.5%
Education
 High school or less72.6%27.4%0.134
 College or more77.0%23.0%
Marital status
 Married69.2%30.8%<0.0001
 Other83.9%16.1%
Body mass index
 18.4 or less85.7%14.3%0.002
 18.5–24.979.2%20.8%
 25–29.966.9%33.1%
 30–34.962.3%37.7%
 35 or more54.5%45.5%
Age at menarch (years)
 12 or less74.0%26.0%0.500
 13 or more74.4%25.6%
Pregnancy
 No89.4%10.6%<0.0001
 Yes67.1%32.9%
Number of pregnancies
 165.4%34.6%0.741
 269.3%30.7%
 3 or more66.4%33.6%
Delivery
 No87.4%12.6%<0.0001
 Yes66.8%33.2%
Number of deliveries
 163.2%36.8%0.120
 2 or more69.3%30.7%
Miscarriage
 No68.6%33.7%0.143
 Yes62.0%38.0%
Cesarean section (401 women)
 No one66.3%33.7%0.360
 One or more69.2%30.8%
Contraception
 Combined pill85.9%14.1%<0.0001
 Progestin pill or hormonal IUD70.4%29.6%
 Other69.6%30.4%
Menopause
 No76.1%23.9%0.011
 Yes64.4%35.6%
Presenting symptom
 Menorrhagia26.7%73.3%<0.0001
 Metrorrhagia63.2%36.8%
 Pelvic pain64.3%35.7%
 Other78.8%21.2%

Abbreviation: IUD, intrauterine device.

Menorrhagia, metrorrhagia, and pelvic pain were the most frequent presenting symptoms. When menorrhagia was the presenting symptom, an ultrasound imaging diagnosis of UL was made in 73.3% of cases (Table 3). Plotting a univariate analysis, metrorrhagia and menorrhagia as presenting symptoms were significantly related to the TVS diagnosis of multiple ULs, but not with the largest UL dimension (Tables 4 and 5). Although lacking statistical significance, patients diagnosed with smaller ULs seemed to be more symptomatic (Table 5).
Table 4

Presenting symptoms according to number of uterine leiomyomas at ultrasound

Presenting symptomUterine leiomyomas at ultrasound
P-value
MultipleSingle
Metrorrhagia72.0%28.0%0.018
Menorrhagia72.7%27.3%
Pelvic pain55.0%45.0%
Other41.9%58.1%
Table 5

Presenting symptoms according to size of largest uterine leiomyoma at ultrasound

Presenting symptomSize of largest uterine leiomyoma
P-value
<3 cm≥3 cm
Metrorrhagia60.0%40.0%0.215
Menorrhagia72.7%27.3%
Pelvic pain75.0%25.0%
Other80.0%20.0%

Discussion

The real prevalence of UL in the general population is unknown. UL prevalence has been evaluated by different methods, such as population surveys,17 pathologic study of surgical specimens of hysterectomy,18 postmortem of women who died without gynecological diseases,19 and pelvic ultrasonography,13,20,21 with, as expected, different results. Kratochwil et al22 introduced ultrasound imaging of feminine pelvic organs in 1972. In 1980, Muram et al23 defined criteria for UL identification with TVS as a relatively spherical mass that is echogenically different from the surrounding myometrium. Since then, TVS has become the most noninvasive, lowest-cost, and widespread method for evaluation of uterine pathology, with highly accurate performance.14–16 The main disadvantage of ultrasound is that it is an operator-and device-dependent technique.24 In order to improve UL diagnosis accuracy, saline contrast sonohysterography and three-dimensional ultrasound have been proposed, although with conflicting results.24,25 Nowadays, two-dimensional pelvic ultrasonography remains the best method for routine detection of ULs.24,25 Ultrasonography has been shown to be an insufficient method of myoma mapping, and magnetic resonance imaging should preferred for surgical therapy planning.25 In the present study, we found a 25.8% overall prevalence of UL, with the highest prevalence (45.4%) in women aged 39–50 years, which is in accordance with previous ultrasound-based studies.13,20,26 Multiple ULs were present in 50.1% of cases, which is lower than that reported in surgical specimens by Cramer and Patel (84%).18 In contrast to Cramer and Patel’s findings, only 49.1% patients had a UL larger than 20 mm. A previous diagnosis of UL had been made in 99 (61.5%) patients, who were in watchful waiting management, which has been considered as a safe management option for asymptomatic UL.27,28 Except in three cases submitted to resectoscopy for treatment of symptomatic submucous myomas, the main component of the leiomyomas was intramural. A purely intramural myoma represents a temporary status, and its growth is dependent on the existing hormonal conditions of the woman.29 Most of the knowledge about demographic and clinical risk factors for UL is based on results of large populations survey studies. Risk factors such as age, ethnicity, education, hormonal factors, diet, physical exercise, oral contraceptives use, childbirth, smoking and tissue injury has been reported, with conflicting results. In accordance with other ultrasound-based studies,13,20,26 after multivariate statistical analysis, we don’t found any demographic or clinical risk factor for UL, with exception of age. The most common symptom of UL is abnormal uterine bleeding, especially menorrhagia.5 The mechanism of leiomyoma-associated menorrhagia is unknown, but submucous localization, vascular defects, and impaired endometrial hemostasis have been suggested as possible explanations.30,31 Even small ULs without distortion of the endometrial cavity can alter myometrial vascularization and contractibility. A meta-analysis conducted by Benecke et al32 reported that intramural ULs may have a negative impact on fertility. In our series, menorrhagia was significantly associated with multiplicity of ULs, but not with the volume of the largest one, suggesting the importance of factors other than those associated with distortion of the myometrium and endometrial cavity. Extracellular matrix that embed UL cells influence both normal myometrial and UL cells, promoting proliferative activity and decreasing apoptosis.33,34 Previous ultrasound-based studies20–35 have reported that the presence, number, and volume of leiomyomas are unrelated to abnormalities in the menstrual cycle. Other studies,36,37 but not all,38 suggest that menstrual symptoms are related to tissue layer location in the uterine wall and with the axial position of leiomyomas. In our study, multiplicity of ULs was significantly related to abnormal uterine bleeding (menorrhagia and metrorrhagia) as a presenting symptom. Currently, most women with menstrual disorders and multiple ULs are scheduled for medical therapy followed by hysterectomy or myomectomy.39 Hysterectomy seems a good option when childbearing wishes have been fulfilled;39 but it is not devoid of risks, morbidity and mortality as for any surgical procedure. Myomectomy is indicated for those women who wish to retain their fertility.39 The major disadvantage of surgical myomectomy is leiomyoma recurrence. In next 5 years, more than one-third of that women submitted to myomectomy will need additional surgical intervention for treatment of newly developed ULs.40 Minimally invasive procedures, such as laparoscopic myolysis, uterine artery embolization, uterine fibroid embolization, and magnetic resonance-guided focused ultrasound, as standard practice for treatment of symptomatic multiple ULs are currently limited.41 It seems obvious that new treatments better than surgical approaches are needed for the management of symptomatic UL. In recent years, intense scientific research has brought new insights on UL biology. The development of ULs has been shown to be dependent of sex steroids, especially progesterone,42,43 and many leiomyoma-related growth factors have been identified, including epidermal growth factor, platelet-derived growth factor, transforming growth factor beta, insulin-like growth factor, activin, and myostatin. We speculate that, in patients with multiple ULs and menstrual disorders, each UL can produce different kinds of growth factors or other biological mediators that may have additive negative effects on the myometrial and endometrial environment. Discovery of selective progesterone receptor modulators (SPRMs) has provided a new paradigm for treatment of symptomatic UL. Antiproliferative, growth factors down-regulation, and proapoptotic actions of SPRMs had been reported in vitro studies over cultured leiomyoma cells.43 Randomized, placebo-controlled clinical trials have demonstrated that the SPRM ulipristal can suppress menstrual bleeding, restore normal levels of hemoglobin, reduce UL volume, and improve leiomyoma-related symptoms.44,45 The main objective of symptomatic UL treatment is to regress symptomatology, because expectant management is suitable for most asymptomatic leiomyomas.27,28 It is expected that new therapies for the treatment of UL-associated symptomatology will be developed, based on the growing knowledge of functional aspects and regulatory mechanisms of leiomyoma biology and uterine homeostasis.

Conclusion

To our knowledge, this is the first population study conducted in Portugal to assess the prevalence and demographic and clinical factors associated with the diagnosis of UL by ultrasound. In our Portuguese population, the prevalence of uterine leiomyoma increases with age, and was similar to that reported in literature for White women. Menorrhagia and metrorrhagia were the more distressing symptoms, especially in patients with multiple ULs diagnosed by TVS. In patients with abnormal uterine bleeding, special attention should be taken to search for multiple leiomyomas during pelvic ultrasound examination. Further studies are needed to assess the biology and symptomatic impact of multiple versus single ULs, in order to find more efficient therapeutic approaches.
  42 in total

1.  The impact of race as a risk factor for symptom severity and age at diagnosis of uterine leiomyomata among affected sisters.

Authors:  Karen L Huyck; Carolien I M Panhuysen; Karen T Cuenco; Jingmei Zhang; Hilary Goldhammer; Emlyn S Jones; Priya Somasundaram; Allison M Lynch; Bernard L Harlow; Hang Lee; Elizabeth A Stewart; Cynthia C Morton
Journal:  Am J Obstet Gynecol       Date:  2008-02       Impact factor: 8.661

2.  Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase IIb study.

Authors:  Lynnette K Nieman; Wendy Blocker; Tonja Nansel; Sheila Mahoney; James Reynolds; Diana Blithe; Robert Wesley; Alicia Armstrong
Journal:  Fertil Steril       Date:  2010-11-05       Impact factor: 7.329

Review 3.  Effect of fibroids on fertility in patients undergoing assisted reproduction. A structured literature review.

Authors:  C Benecke; T F Kruger; T I Siebert; J P Van der Merwe; D W Steyn
Journal:  Gynecol Obstet Invest       Date:  2005-03-15       Impact factor: 2.031

Review 4.  Growth factors and cytokines in uterine leiomyomas.

Authors:  J Andersen
Journal:  Semin Reprod Endocrinol       Date:  1996-08

5.  Value of magnetic resonance imaging in diagnosis of adenomyosis and myomas of the uterus.

Authors:  Charalampos P Stamatopoulos; Themistoklis Mikos; Grigoris F Grimbizis; Athanasios S Dimitriadis; Ioannis Efstratiou; Panagiotis Stamatopoulos; Basil C Tarlatzis
Journal:  J Minim Invasive Gynecol       Date:  2012 Sep-Oct       Impact factor: 4.137

6.  Predictors of subsequent surgery for uterine leiomyomata after abdominal myomectomy.

Authors:  Elizabeth A Stewart; Adriana V Faur; Lauren A Wise; Raymond J Reilly; Bernard L Harlow
Journal:  Obstet Gynecol       Date:  2002-03       Impact factor: 7.661

Review 7.  Growth factors and myometrium: biological effects in uterine fibroid and possible clinical implications.

Authors:  Pasquapina Ciarmela; Md Soriful Islam; Fernando M Reis; Peter C Gray; Enrrico Bloise; Felice Petraglia; Wylie Vale; Mario Castellucci
Journal:  Hum Reprod Update       Date:  2011-07-25       Impact factor: 15.610

8.  Racial differences in fibroid prevalence and ultrasound findings in asymptomatic young women (18-30 years old): a pilot study.

Authors:  Erica E Marsh; Geraldine E Ekpo; Eden R Cardozo; Maureen Brocks; Tanaka Dune; Leeber S Cohen
Journal:  Fertil Steril       Date:  2013-03-15       Impact factor: 7.329

Review 9.  Long-term use of progestogens--effects on endometriosis, adenomyosis and myomas.

Authors:  Karl-Werner Schweppe
Journal:  Gynecol Endocrinol       Date:  2007-10       Impact factor: 2.260

10.  Current and emerging treatments for uterine myoma - an update.

Authors:  Nirmala Duhan
Journal:  Int J Womens Health       Date:  2011-08-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.